04

2024

-

08

Lancet sub-journal, Guangdong Provincial People's Hospital Wu Yilong and other teams reported for the first time the latest results of terpolitinib combined with oxitinib in the treatment of EGFR mutant non-small cell lung cancer patients!

Author:


Patients with EGFR-mutated non-small cell lung cancer (NSCLC) and MET amplification as mechanisms of first-line osimertinib resistance have few treatment options.

On August 2, 2024, Wu Yilong of Guangdong Provincial People's Hospital and Tae Min Kim of Seoul University of South Korea jointly communicatedLancet Oncology(IF=41.6)Published online entitled“Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial”The research paper,The study conducted aMulticenter, open-label, phase 2 trial of terpolitinib in combination with osimertinib in patients with EGFR-mutated non-small cell lung cancer.

The results of the study show that terportinib combined with osimertinib shows good activity and acceptable safety in patients with EGFR-mutated NSCLC and MET amplification, as a mechanism of first-line osimertinib resistance, which indicates that a potential chemotherapy-sparing oral targeted treatment regimen needs to be further studied.

MET amplification is the most common secondary driver of resistance to EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The reported incidence of MET amplification in EGFR TKIs-resistant EGFR mutant NSCLC varies and is estimated to be between 10% and 66% depending on the method of detection and definition. MET amplification was more common in osimertinib (the preferred standard of care for third-generation EGFR TKIs and previously untreated EGFR mutant NSCLC) than in previous generations of EGFR TKIs. After EGFR TKI therapy, clinical practice guidelines recommend thorough detection of resistance mechanisms, including MET amplification, to guide subsequent therapy. So far, the treatment after the failure of EGFR TKI is still platinum-based chemotherapy. Simultaneous inhibition of MET and EGFR may beEGFRmutant NSCLC patients who present after progression of EGFR TKIs provide a therapeutic advantageMETAmplification.

Terbolitinib is a highly selective oral MET TKI approved for the treatment of advanced or metastatic MET exon 14 skipping NSCLC5 and is recommend as a treatment option for NSCLC with high levels of de novo MET amplification. Due to its high selectivity, terpolitinib shows a low risk of off-target toxicity and can be used in combination with EGFR TKIs. Preclinical and clinical studies have supported the combination of terpolitinib and EGFR TKIs in the treatment of NSCLC with EGFR mutations and Met amplification.Phase 2 INSIGHT trials have shown that for EGFR-mutated, Thr790Met-negative, MET-amplified NSCLC patients, terpolitinib combined with gefitinib has a better clinical benefit than chemotherapy, and the disease of these patients has progressed on previous EGFR TKIs.

Analysis of anti-tumor activity in the main active population

The study enrolled 128 patients (74 [58%] female, 54 [42%] male) and started terpolitinib + osimertinib between 13 February 2020 and 4 November 2022. The primary activity analysis population included 98 patients with MET amplification confirmed by central FISH, previous first-line osimertinib therapy, and were followed for at least 9 months (median 12.7 months [IQR 9.9-20.3]). The objective response rate for diagnosis was 50.0 (95% CI 39.7 - 60.3; 49 of 98 patients). The most common treatment-related adverse events of grade 3 or higher were peripheral edema (6 [5%] of 128 patients), decreased appetite (5 [4%]), electrocardiographic QT interval prolongation (5 [4%]), and pneumonia (4 [3%]). Serious treatment-related adverse events were reported in 16 (13%) patients. The investigators assessed 4 (3%) deaths as possibly related to any of the trial drugs, including pneumonia (2 [2%]), decreased platelet count (1 [1%]), respiratory failure (1 [1%]), and dyspnea (1 [1%]);1 death was attributed to pneumonia and dyspnea.

In conclusion, the study shows that terpolitinositinib has a significant impact onEGFRMutated NSCLC patients, whose disease has progressed under first-line osimertinib treatment and who have MET amplification, provide promising clinical benefit and manageable safety.The results of the study indicate that terpolitinositinib is a potential chemotherapy-saving oral targeted treatment option that may help address the high unmet medical need in this situation, as it provides an effective regimen with a manageable safety profile that enables patients to defer any IV treatment burden.

Chongqing Chongfan Technology Co., Ltd. Optical platform film thickness meter OCT optical coherence tomography LabVIEW control